Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Afficher d'autres versions (1)

Détails bibliographiques
Auteurs principaux:	Stratford, M, Folkes, L
Format:	Journal article
Publié:	2011

Documents similaires

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
par: Stratford, MR, et autres
Publié: (2011)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
par: Stratford, MR, et autres
Publié: (2012)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
par: Stratford, MR
Publié: (2008)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation
par: Stratford, M, et autres
Publié: (2012)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation.
par: Stratford, MR, et autres
Publié: (2012)

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
par: Patterson, D, et autres
Publié: (2012)

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
par: Rustin, G, et autres
Publié: (2003)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
par: Rustin, G, et autres
Publié: (2010)

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals.
par: Folkes, L, et autres
Publié: (2007)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
par: Cummings, J, et autres
Publié: (2012)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
par: Cummings, J, et autres
Publié: (2012)

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
par: Nathan, P, et autres
Publié: (2012)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
par: Galbraith, S, et autres
Publié: (2001)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
par: Prise, V, et autres
Publié: (2002)

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
par: Nathan, P, et autres
Publié: (2008)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
par: Jane Lunt, S, et autres
Publié: (2011)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
par: Lunt, S, et autres
Publié: (2011)

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
par: Zweifel, M, et autres
Publié: (2009)

Photolysis of 1-Octene and Molybdenum Hexacarbonyl in Tetrahydrofuran
par: Card, Roger J., et autres
Publié: (1977)

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
par: Brooks, A, et autres
Publié: (2003)

1-De-oxy-d-arabinitol.
par: Jenkinson, S, et autres
Publié: (2008)

1-De-oxy-1-fluoro-l-galactitol.
par: Jenkinson, S, et autres
Publié: (2010)

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
par: Meyer, T, et autres
Publié: (2009)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
par: Thomson, P, et autres
Publié: (2006)

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
par: Zweifel, M, et autres
Publié: (2011)

1,5-Di-meth-oxy-naphthalene.
par: Marfo-Owusu, E, et autres
Publié: (2013)

1-De-oxy-l-mannitol (6-de-oxy-l-mannitol or l-rhamnitol).
par: Jenkinson, S, et autres
Publié: (2008)

1-Carb-oxy-methyl-3-octylimidazolium bromide
par: Al-Mohammed, N.N., et autres
Publié: (2011)

1-De-oxy-d-galactitol (l-fucitol).
par: Jenkinson, S, et autres
Publié: (2008)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
par: Tozer, G, et autres
Publié: (2001)

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
par: Nathan, P, et autres
Publié: (2007)

Effect of Column Inlet and Outlet Geometry on Large-scale HPLC
par: Tan, S.N., et autres
Publié: (2003)

1-[4-(Prop-2-en-1-yloxy)benzyl]-2-[4-(prop-2-en-1-yloxy)phenyl]-1H benzimidazole
par: Hegde, Gurumurthy, et autres
Publié: (2012)

MEDI 570-Synthesis and photolysis studies of caged TRPV1 agonists and antagonists
par: Conway, S, et autres
Publié: (2006)

Synthesis, photolysis studies and in vitro photorelease of caged TRPV1 agonists and antagonists.
par: Ryssen, V, et autres
Publié: (2009)

Narrow bore HPLC columns with chemically bonded phase on porous glass /
par: Lodkowski, R

1,1 `-{[1,4-Phenylenebis(methylene)]bis(oxy)bis(3,1-phenylene)}diethanon e
par: Al-Mohammed, N.N., et autres
Publié: (2011)

1,1 `-{[1,4-Phenylenebis(methylene)]bis(oxy)bis(4,1-phenylene)}diethanon e
par: Al-Mohammed, N.N., et autres
Publié: (2011)

N-Benzyl-1,3-dide-oxy-1,3-imino-l-xylitol.
par: Jenkinson, S, et autres
Publié: (2011)

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
par: Tozer, G, et autres
Publié: (2009)